Abstract: Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.

Abstract: Compounds of the formula: are disclosed useful for treating osteoporosis, obesity, breast cancer, endometriosis, cardiovascular disease and prostatic disease. Substituents A, B, E, D, Z1, G, Y and e have the same meaning as defined in the specification.

Abstract: The compound is a neuropeptide Y antagonist and is effective in treating feeding disorders, cardiovascular diseases and other physiological disorders.

Abstract: This invention provides a means of inhibiting or preventing a disease or condition associated with an excess of neuropeptide Y which comprises administering to a mammal in need of such treatment an effective amount of a compound of the formula: wherein R1 is a nitrogen containing heterocyclic compound.

Abstract: Compounds of the formula are effective for the treatment of conditions in mammals which require inhibition of the action of substance P.

Abstract: Compounds of this formula ##STR1## are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.

Abstract: A new pyridine carbaldehyde is useful for the synthesis of compounds which are effective for treating neurodegeneration conditions and CNS trauma.

Abstract: A method of treating conditions associated with neuropeptide Y which comprises administering a compound of the formula ##STR1## to a mammalian subject in need of such treatment.

Abstract: This invention provides novel antibodies and engineered versions thereof and methodology for monitoring biological media for protein fragments, especially collagen fragments resulting from collagenase cleavage of type II collagen.

Abstract: A method for preparing hydroxamic acid derivatives which are useful as analgesic, antiinflammatory, or neuroprotective agents.

Abstract: Substituted tetralins, chromans and related compounds which, by inhibiting 5-lipoxygenase enzyme and/or blocking leukotriene receptors, are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related disease states in mammals, pharmaceutical compositions thereof, a method of treatment therewith, and to intermediates useful in the synthesis thereof.

Abstract: A process for preparing the compound of formula (1) is disclosed. ##STR1## The starting materials are an N-triazolylmethyl-6-aminoisoquinoline and a 4-biphenyl-2-carboxylic acid derivative.

Abstract: The present invention provides novel methods of inhibition of autoimmune diseases comprising administering to a mammal in need of treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is hydrogen or a benzyl group; or a pharmaceutically acceptable salt thereof.

Abstract: Indole carboxylic acids are useful as UGGTASE inhibitors.

Abstract: Compounds of formula I are useful in treatment of conditions associated with depletion of nicotine receptors in mammals.

Abstract: (-)Cis-6(S)-phenyl-5(R)-?4-(2-pyrrolidin-1-yl ethoxy)phenyl!-5,6,7,8-tetrahydro-naphthalen-2-ol D-tartrate, pharmaceutical compositions comprising this compound, and an advantageous process for preparing the compound.

Abstract: The dimesylate salt of cis-1-(3-ethoxyphenyl)-1-(4-phenylpiperazin-1-yl)4-methyl-cyclohexane has superior properties and is useful to treat physiological disorders associated with an excess of neuropeptide Y.

Abstract: Use of droloxifene in the treatment of cardiovascular diseases.

Abstract: This invention encompasses compounds of formula (I) and the pharmaceutically ##STR1## acceptable salts thereof, wherein W,X,Y,A,T,R.sub.1 -R.sub.4,B,Ar,n and m are described herein and are useful in treating feeding disorders and certain cardiovascular diseases due to the binding of these compounds to human Neuropeptide Y1 receptors.

Abstract: The present invention provides novel methods of inhibiting bone loss comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is a hydrogen or a benzyl group; or a pharmaceutically acceptable salt thereof; together with or in combination with parathyroid hormone.